Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4

Aligos Therapeutics, Inc.

2024-Q2 EPS reported -$0.19 revenue$1,755,000

Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.
Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.
R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).
ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.
ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.